NeoGraph Analytics
Medical DevicesNorth America2023 – 2032

Global United States Continuous Glucose Monitoring Market Size, Share and Trends Analysis

The United States CGM market was valued at $3.8B in 2023, projected to reach $15.0B by 2032 at 16.5% CAGR.

Revenue, 2023

$3.8B

Forecast, 2032

$15.0B

CAGR, 2024-2032

16.5%

Report Coverage

North America

Code: united-states-continuous-glucose-monitoring-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The U.S. continuous glucose monitoring market was valued at approximately USD 3.8 billion in 2023 and is projected to reach USD 15.0 billion by 2032, growing at a CAGR of 16.5%. Dominated by Dexcom and Abbott, the market is driven by rising diabetes prevalence, FDA approvals, and integration with insulin pumps. Real-time CGM leads adoption, with Type 1 diabetes patients representing the largest user segment. Expanding insurance coverage and wearable technology convergence present significant growth opportunities.

02

Key Highlights

1

U.S. CGM market projected to reach USD 15.0B by 2032 at 16.5% CAGR from USD 3.8B in 2023

2

Dexcom and Abbott collectively control over 75% of the U.S. CGM device market share

3

Consumer wellness CGM segment expected to grow fastest as non-diabetic users adopt glucose tracking

03

Market Overview

Market Context

The U.S. CGM market is in a high-growth phase driven by 37M+ diabetic patients, expanding PBM coverage, and next-generation sensor accuracy. Dexcom and Abbott lead, while closed-loop integration and consumer wellness expansion redefine competitive boundaries.

The U.S. CGM market is experiencing high growth fueled by over 37 million diabetics, increasing physician adoption, and next-gen sensor accuracy. Dexcom G7 and Abbott FreeStyle Libre 3 lead the competitive landscape with closed-loop integration reshaping treatment protocols.

Market Stage

High growth

Adoption Level

Growing

Key Trends

Integration of CGM with automated insulin delivery (AID) systemsExpansion into non-insulin-dependent Type 2 diabetes patientsConsumer wellness CGM adoption driven by Abbott Lingo and SteloAI-powered predictive alerts improving hypoglycemia management
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 16.5%

Base Year (2023)

$3.8B

Forecast (2032)

$15.0B

CAGR (2024-2032)

16.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$3.80B
2024$4.43B
2025$5.16B
2026$6.01B
2027$7.00B
2028$8.15B
2029$9.50B
2030$11.07B
2031$12.89B
2032$15.02B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

Valued at USD 3.8B in 2023, the market is forecast to reach USD 15.0B by 2032 at 16.5% CAGR. Real-time CGM dominates at 65% share. Type 2 diabetes adoption and consumer wellness are the fastest-growing demand segments through 2032.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America42.0%16.8%United States
Europe30.0%14.5%Germany
Asia Pacific28.0%18.5%China

North America

#1
Share: 42.0%CAGR: 16.8%

Largest market: United States

Europe

#2
Share: 30.0%CAGR: 14.5%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising diabetes prevalence across all age groups in the U.S.
  • FDA-cleared non-adjunctive use expanding patient eligibility
  • Payer coverage expansion by major U.S. PBMs
06

Market Segmentation

By Type
Market share distribution across 2 segments
By Type — market share by segment, in percent.
SegmentShare
Real-Time CGMDominant segment providing continuous glucose readings with real-time alerts and smartphone connectivity.65.0%
Flash CGMScan-based systems offering on-demand glucose readings without continuous data transmission.35.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Application
Market share distribution across 3 segments
By Application — market share by segment, in percent.
SegmentShare
Type 1 DiabetesLargest application segment driven by insulin-dependent patients requiring constant glucose monitoring.55.0%
Type 2 DiabetesFastest-growing segment as CGM adoption expands beyond insulin-dependent populations.35.0%
OthersIncludes gestational diabetes, prediabetes, and consumer wellness applications.10.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Home Care Settings
  • Diabetes Clinics
07

Regional Analysis

1

North America

Lead: United States
CAGR: 16.8%Share: 42.0%

Largest market driven by high diabetes prevalence, advanced healthcare infrastructure, and strong insurance coverage.

2

Europe

Lead: Germany
CAGR: 14.5%Share: 30.0%

Growing adoption supported by national healthcare reimbursement and rising Type 2 diabetes cases.

3

Asia Pacific

Lead: China
CAGR: 18.5%Share: 28.0%

Highest growth region due to expanding diabetic population and increasing healthcare expenditure.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
42.0%
+16.8%
Germany
14.0%
+14.2%
China
12.0%
+19.5%
08

Competitive Landscape

D

Dexcom, Inc.

United States

Leader3.3B

Dominates U.S. CGM with G7 system; all major PBMs provide coverage reaching 6M+ eligible patients.

U.S.-based market leader in CGM technology known for the G7 real-time system with factory calibration and 15-day sensor wear.

A

Abbott Laboratories

United States

Challenger1.2B

FreeStyle Libre franchise targets $10B in sales by 2028; Lingo CGM expands into consumer wellness segment.

Global healthcare company with the FreeStyle Libre franchise targeting USD 10B in franchise sales by 2028 and expanding into consumer wellness.

M

Medtronic plc

Ireland

Follower0.8B

MiniMed 780G with Simplera Sync sensor offers integrated closed-loop insulin delivery system.

Ireland-headquartered medtech giant offering integrated closed-loop insulin delivery with the MiniMed 780G and Simplera Sync sensor.

09

Recent Developments

25
2025Dexcom

Expanded coverage through all three major U.S. PBMs reaching over 6 million eligible patients

24
2024Abbott Laboratories

Launched Lingo CGM for consumer wellness market targeting non-diabetic users

10

Regulatory Landscape

FDA 510(k) clearance pathway for Class II CGM devices with non-adjunctive use labelingCMS Medicare coverage expansion for CGM devices under durable medical equipment benefit
11

Research Methodology

Primary research

  • Expert interviews
  • Surveys

Secondary research

  • Industry reports
  • Company financials

Validation: Triangulation method

12

Strategic Takeaways

Investors

The 16.5% CAGR through 2032 signals strong ROI potential in CGM device and consumable portfolios.

Operators

Differentiation through AI-driven analytics and closed-loop integration will define market leadership.

Payers

Expanding CGM coverage improves outcomes and reduces long-term diabetes complication costs.

Clinicians

CGM adoption is becoming standard of care across both Type 1 and insulin-naive Type 2 populations.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.